Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -22.89% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.89% | -- | |||
| Cost of Revenue | -14.75% | 127.53% | |||
| Gross Profit | 14.42% | -118.81% | |||
| SG&A Expenses | 22.10% | -5.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.00% | 38.42% | |||
| Operating Income | -3.50% | -35.79% | |||
| Income Before Tax | -253.00% | -76.62% | |||
| Income Tax Expenses | 914.29% | -300.00% | |||
| Earnings from Continuing Operations | -253.40% | -76.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -253.40% | -76.60% | |||
| EBIT | -3.50% | -35.79% | |||
| EBITDA | -3.24% | -35.91% | |||
| EPS Basic | -448.97% | 5.88% | |||
| Normalized Basic EPS | -182.94% | -1.51% | |||
| EPS Diluted | -21.26% | 26.59% | |||
| Normalized Diluted EPS | -261.27% | -49.35% | |||
| Average Basic Shares Outstanding | 84.47% | -76.29% | |||
| Average Diluted Shares Outstanding | -5.13% | -53.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||